Axcella Health (AXLA) Misses Q4 EPS by 4c

Axcella Health (NASDAQ: AXLA) reported Q4 EPS of ($0.40), $0.04 worse than the analyst estimate of ($0.36).

“The year 2020 was a key inflection point for Axcella as we completed multiple clinical studies with positive results and shifted our full attention to our upcoming later-stage clinical trials,” said Bill Hinshaw, President and Chief Executive Officer of Axcella. “We were pleased to advance our preparations in the fourth quarter with a successful Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding our nonalcoholic steatohepatitis (NASH) candidate, AXA1125, and began 2021 with our first investigational new drug (IND) clearance for AXA1665, our candidate for the reduction in risk of recurrent overt hepatic encephalopathy (OHE). Axcella’s strong execution has positioned us for an exciting year ahead as we seek to swiftly enroll our upcoming trials, expand our pipeline of EMM compositions and further our mission to improve the lives of patients with complex diseases.”

For earnings history and earnings-related data on Axcella Health (AXLA) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb